About the Authors

The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.

Disclaimer

"Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.

Become a Fan

October 29, 2012

Biotech Venture Funding Up 64% in Third Quarter

Earlier
this month, the National Venture Capital Association (NVCA), a
trade association representing the U.S. venture capital industry, released the
results of its MoneyTree Report on venture funding for the third quarter of
2012. The report, which is prepared by NVCA and PriceWaterhouseCoopers
LLP using data from Thomson Reuters, indicates that venture capitalists
invested $6.5 billion in 890 deals in the third quarter, which constituted a
12% decrease in dollars and a 5% decrease in deals as compared with the second quarter
of 2012, when $7.3 billion was invested in 935 deals (see chart below; data from MoneyTree Reports). The NVCA also
revised its second quarter numbers, raising the funding and deals totals by
$300 million and 37, respectively (see
"Venture Funding in Life Sciences Sector Drops 9% in Second Quarter").

While
the report indicates that the venture funding in the Life Sciences sector
(biotechnology and medical device industries) was down 19% in dollars and 12%
in deals for the first three quarters of 2012 as compared to the first three
quarters of 2011, investment in biotechnology increased by 64% in dollars to
$1.2 billion and 22% in deals to 116 in the third quarter. Second quarter investment in biotechnology had
dropped below $1 billion and 100 deals (see chart below; data from MoneyTree Reports).
The report also noted that medical device funding declined for the third
consecutive quarter, falling 37% in dollars and 27% in deal volume with $434
million going into 65 companies, which constituted the lowest dollar level of
investment in the industry since 2004. Overall,
seven of the seventeen sectors tracked by the NVCA saw increases in dollars
invested in the third quarter (in the second quarter, eleven of seventeen
sectors saw increases).

NVCA
president Mark Heesen noted that "[t]he third quarter numbers tell a story
consistent with investment themes we have been seeing throughout 2012,"
pointing out that "life sciences investment remains low, reflecting
ongoing concerns regarding regulatory uncertainty, capital intensity and
investment time horizons in the space."
Tracy Lefteroff, the global managing partner of the venture capital
practice at PricewaterhouseCoopers, observed that "fewer new venture funds
[were] being raised which means less capital is available for new
investments." Stating that
"venture capitalists [have been] very cautious with the capital that is
available," she noted that they were instead "continuing to support
the companies already in their portfolio."

For additional information regarding this and other related topics, please see: